How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain
In This Article:
BioMarin said Friday it would spend $270 million to acquire Inozyme Pharma, sending shares of the latter skyrocketing by triple digits.
Oops, something went wrong
BioMarin said Friday it would spend $270 million to acquire Inozyme Pharma, sending shares of the latter skyrocketing by triple digits.